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Bscause thromhus flN3llihl is ala important source of 
~li)~~id;ty during i~I~~i(~~l~lStV (3.1). t~~~~~~llb~)lyt~C tIlC~ p)r 1124 
hccn Used in altempts to ikprovvc angioplasty outcome and 
&crease complications. However, tllr~~~~~9[~ly~is could have il 
IlCgiltiVC impact 1111 angioplasty 0utc0mc ali the rcSult of 
promoting hcmorrhngc within the athcrosclcrotic plaque. Fur- 
thermore. in some settings tl IllhOlytic ilgemS hVC btX1~ 
shown to hiWe a prothromhotic (5). This review discusses 
the itvailitble data O~I thr{)~~~9~~lyt~c therapy HIS ~1 adjunct to 
angioplasty. 
There are inherent limitations in any review, the most 
prominent of which is heterogeneity among the studies being 
cvahmted. Thus, ditkrent thrombolytic agents were adminis- 
tered in varying dosages and by vqing routes. Operational 
definitions of angioplasty success and xutc occlusion may 
differ from one investigation to the next. Some of the questions 
addressed in this review were evaluated in randomized, con- 
trolled trials, but many of these areas have been the subject of 
only rc:rospectivc or uncontrolled studies. Thus, it is not 
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pnSSil7lC I\) tlfiIW nmclusions 011 tlK rL_!lii(iVl’ men’it!3 08 tilt 
drkre~lt t~lr~)~~~~lO~yt~c ajicnls or sfratcgics hccausc they lye 
it ~CCU ~4uat~d in randomized. controlled trials. 111 an 
attempt to synthesize the available data, we undcriook pooling 
of puhlish~d studies where appropriate (6). Admittedly, pool- 
ing may okurc important differences in trial design and 
quality. klts~c~er. the results of the individtml studies arc 
provided, znd the relevant clcmcnts of study design arc 
highlighted t~ir~~ugl~{~Mt this review. 
The rcportcd frcqucncy of acute occlusion complicating 
~Ill~iO~~li~Sty hit!4 l2lllgCd fKNl1 7!,i, to I 1’; (7), with ;In incidence 
of 4.4”i (3) and G-Y; (I) in llw I:lrgcst scriss lo date. ‘l‘hrcc 
studies ll2W CO~llpillTd thC OUtclMll0 of ~lngiOpli~:;t~ ill il group 
of ~atjcllts rccciving rou~inc administration of mxGasc lx- 
fort or during elcctivc itingi@My with a control group not 
receiving thromholytic agents hut undergoing treatment with 
varying regimeas of antiplatelet agents and heparin (X-IO). 
Two of rhcsc studies were randomized and prospective (KY), 
and the third was ;I retrospective review (IO). Although all 
three studies evaluated the impact of thromholysis in clectivc 
angioplasty, two studies included patients with unstahlc angina 
(IX% [ 101 and 20% [Xl of the total patient populatic~9). The 
outcome in patients with unstable angma was no1 rcportcd 
separately from the outcome in patients with stiII?Ic angina. 
Figure I shows the odds ratios for angioplasty SUCCCSS id 
acute occlusion rates for the individual studier and the pooled 
total (13). There was no significant ditfcrcnce Bbr as,gioplasty 
success rates (odds ratio I XI, Wk confide~~ce imcrva~ [c’i] 
0.85 to 2.17) or acute occlusion rates (odds ratio 0.X9, 05’G C’I 
(I.47 to 1.60) in any of the illdiVidl.liil studicb or the ptj(jled 
totals. 
There were 742 patients in tllu p~lcd analysis, will1 iIll 
87.2~ success rate and a 5.9% acute ocrlnsilm rate in c~~tr~~i 
patients. Therefore, this pooled analysis had ~1 XW ]w’cr 10 
detect an improvomcnt in the angioplasty success rate to 
93.6% (a 50% decrease in the ritk? of failure of a~~~~)pl~~sly) 
and a 50% improvement in angioplasty complication rates (to 
3.0%). To detect an improvement in the angioplasly success 
rate to 90.4% (a 25% decrease in angioplasty failure), the 
anatysis would require a sample of 1,531 patients. To detect a 
25% reduction in the complication rate, the sample size would 
need to be 5,503. Table I lists the beta errors of the individual 
trials (assuming a desired alpha error of 0.05) to detect a 50% 
improvement in angioplasty succe.ss and complication rates. 
The small size of the individual studies limits their ability to 
detect a clinically important difference. Although the av;rilablc 
data do not S\JPPOZ F he hypothesis that routine thrombolytic 
therapy in electtve angiophrsty will result in ii 50% i~~~r~~v~~ 
ment in a@oplasty success and complications. a more modest 
F&yre 1. Ampact of antcccdcnt tl~r~n~~~~ 
lytic thwpy on success rates (le 
complication rates (right) for elective an- 
giopktsty. Odds ratios and 95% confidence 
intcrwls for the individucrl studies and the 
p~olled results :lre shown. 
eating a~~io~~asty are increased in the setting of unstable 
angina. 
The c@cacy of tbr~~~~b~~~~ti~ thera for acute myo~ardia~ 
infarction has been firmly established, but a similar benefit in 
unstable angina cannot be automaiieally assumed. The com- 
position of coronary thrombi in unstable angina and myocar- 
dial infarction may differ substantially (16). Studies examining 
the use of thro~,lbolytic therapy in patients with unstable 
angina have failed to es,tablisb a clinical benefit for tbrombol- 
ysis (17-26). Whether thrombolytic therapy in this setting can 
improve the outcome cd angioplasty has been the subject of 
numerous investigations. 
~n~iQ~~~~~~c appearance. Table 2 summarizes the studies 
that kave evaluated the impact of thrombolysis on the angio- 
graphic appearance of coronary lesions in patients with unsta- 
ble angina (18.19,22,23,~!7-33). Most of these studici analyzed 
angiograms before and after a course of thrombolytic therapy 
and measured the change in coronary stenosis severity. Uni- 
formly, the stenosis severity showed a trend toward lessening, 
although this reached statistical s~g~~~ca~~e in only four stud- 
ies (l&19,23,28). Furthermore, when control patients treated 
with heparin and aspirin were evaluated, as was done in the 
majority of studies, stenosis severity in the control group 
lessened to a similar degree as that in the thrombolysis group 
(23.27,29,32,33), with one notable exception (1X). However, 
most of these studies were fairly small and had limited power 
to detect a significant difference. 
Four studies (17.21,29,32) have evaluated the frequency of 
intracoronary thrombus identified on angiography in patients 
with unstable angina after treatment with thrombolytic rher- 
apy. These studies did not obtain baseline angiograms before 
treatment was initiated. The rate of intracoronary thrumbi n 
patients receiving thrombolysis (21 of 78 [27%]) was -50% 
that in control patients (37 of 74 [50%]), suggesting that 
thrombolysis effected clot dissolution. 
Ten studies (20,27-20,34-40) with baseline angitsgraphy 
before the initiaiion of therapy have examined the fate of 
intracoronary thrombi. Three of these studies (27,29,35) pro- 
vided a control group with intracoronary thrombus who did not 
receive thrombolytic therapy but received antithrombotic ther- 
apy for 24 to 48 h. Bf 139 patients with intracoronary thrombus 
who received thrombolytic therapy, reduction or resolution of 
the thrombus was evident in 113 (81%) compared with 44 
(80%) of 55 control patients. In the only randomized, con- 
trolled, prospective trial (27), the frequency of clot reduction 
did not differ, but the degree of thrombus dissolution was 
greater in patients receiving thrombolysis. There was a notable 
variability in the response to thrombolytic therapy in individual 
patients (27) in that some patients demonstrated improvc- 
ment, whereas in others the severity of stenosis increased (27), 
including progression to complete occlusion (l&28-30). In 
several of the studies, follow-up angiography assessing the 
changes in intracoronary thrombus was delayed from 18 to 72 h 
(27,28,36). This is an important confounding variable because 
extended antithrombotic therapy with aspirin and heparin has 
been shown to be associated with improvement orresolution of 
intracoronary thrombus (40). Several studies using immediate 
angiographic follow-up reported angiographic mprovement in 
45 (73%) of 62 thrombi, suggesting that the changes in the 
angiographic appearance of thrombus may be, in part. attrib- 
uted to the thrombotytic therapy (.&34-M). 
Nine studies (18,19,27,29,33-36) have reported the out- 
cume cf thrombolytic therapy in patients with unstable angina 
and total occlusion of the culprit coronary artery. Of 69 
patients tudied, thrombolysis achieved patency in 39 (57%). 
Of 27 control patients treated with aspirin and heparin, 
patency was established in 4 (15%). Data on the outcome of 
angioplasty inthis patient subgroup are limited to a report (36) 
of two patients who underwent succrssful angioplasty after 
receiving thrombolylic agents. 
Thus, the overall frequency of clot dissolu?ion appears 
similar in patients receiving thrombolysis and those wceiving 
24 to 48 h of hcparin and aspirin. Thrombolysis appears to 
permit these changes to occur sooner and, in some cases, to a 
greater degree than antithrombotic therapy. 
Aslgioplasty outcome. Whether the modest angiographic 
improvement with thrombolysis n patients with unstable an- 
gina translates into improved angioplasty results has been 
addressed in six studies (29,37,42-45) (Fig. 2). One study (37) 
demonstrated a significant improvement inangioplastj success 
rates, whereas another demonstrated a lower rate of angio- 
plasty success with antecedent thrombolysis (45). The pooled 
result did not reveal an improvement in angioplasty success 
rates with thrombolysis (odds ratio 1.18,95% CI 0.54 to 2.57). 
The largest study to date (45) reported a significant increase in
abrupt closure rates among patients treated with urokinax. 
The trend for a detrimental effect did not reach signilicawes: 111 
the pouled analysis (odds ratio 1.40, 95% CI 0.79 to 2.47). 
The published data on the impact of thrombolysis on 
aqiopl:lsty success in unstable angina includes 204 patients 
with an 85.8% angioplasty success rate in the control group. 
This pooled analysis is underpowered. To achieve 80% cer- 
tainty of detecting an improvement in the angioplasty SUCCCSS 
rate to 92.9% (a 50% reduction in angioplasty failure) or 
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X$4% (a 25% reduction in illlgiOplil!Q failurr) would rcquirc 
ZW and 1,363 patients, rcspcctivcly. The beta errors of the 
individual trials iWC summarbcd in Table 1. 
The published data on abrupt closure complicating angio- 
plasty include 3% patients. The abrupt closure rate among 
control patients was 8.2%: among patients trcntcd with throm- 
bolytics it was 9.4%. To detect a 2SCi or SQ% &Oti~SC in t 
ilbrllpt closure rilk would require 2.W and ShO 9Wticn 
respectively. 
The Thromholysis in Myoc*irdial Ischcmia (T9M9)-~~ trial 
(46). which randomized 902 patients with ~t~~tahlu it@I;l. 
bund no impact of untcccdent thrombolysis on il~~~il~~hls~y 
success and complication rates. 1 Iowcvcr. ;1 dcriailcd tcport of 
~ll~g9t~~l~~s~y outcome in this trial has not yet been ptll~l~she~9. 
Also, the Thrombolysis and Angioplasty in lJnstt\blc Angina 
(TAUSA) trial (4s) investigak~rs have reported ~rclim9~~1~ 
data on abrupt closure during angioplasty. but information 
concxAng angioplnsty success rates has not ycr been puh- 
lishcd. 
tients with unstably angina an 
id icnts with unstable angina and 
~n~~~~raphicilll~ demonstrable intncoronary thrombus are at 
parkularly increased risk of complications during angioplasty 
(3,4&U). FOUP retrospective studies (35,3X,30,42) have exam- 
in~d the i~~p.~t of thrombolytic therapy on ~~ngiopt~~s[y out- 
come in these patients. Overall angiopli~sty succc~s was 
achieved in 20 (cI: 3) of 22 patients with intracoronq throm- 
bus who re:LP‘iv~~d thromholytic agents. ,~ngiopl~~s~y success 
rates for control patients receiving aspirin and heparin hut not 
thrombolytic therapy were not reported in any of these trials. 
However. complications of angioplasry occurred in 3 (6%) of 
52 treated patients and 5 (19%) of .?7 control patients. The 
strategy of de9ay9ng angiopiasty for several days of aspirin and 
intravenous heparin therapy has been shown to reduce com- 
plication rates and increase angioplasty success rates (41). No 
direct comparison of thrombolytic therapy before angiop9asty 
this group of patients is not y& avaiiablc. 
role 
The outcome of angioplnsly is associated with diminished 
success rates in chronically occluded vessels compared with 
patent vessels. The possibility that thrombus formation con- 
tributes to the dcvclopment of chronic total occlusions has 
prompted some investigators to attempt prolonged intracoro- 
naq urokinasc infusions to achieve vessel patency and pro- 
mote il~@phSty Success. Seven studies (49-S) hilVC cxam- 
incd the utility of prolonged urokitlase infusion in rec~~~~9izing 
chronically occluded saphenous vein grafts. Urokinase dosage 
ranged from 36.W to 31H),o(M) U/h. Patency was achieved in 
74% of cases. Although the specific definitions for recanaliza- 
tie!: were not specified in the majority of the reports, it is dear 
that in many cases the degree of flow that was established by 
thrombolysis alone was insufficient to adequately alleviate 
ischemia. Subsequent angioplasty was performed in 43 patients 
and was successful in all. In three studies (56-58) of prolonged 
cardial i~~farctii~U has been reported (49-5 P .54,(96) as a 
WI ation of Q~olo~l~ed thrombolytic infusions in c 
tally occluded sapbenous vein grafts. Furthermore, the 
nalizition of Chronically Occluded Bypass Gr 
longod Urokinasc Infusion Site Trial (R 
investigators have reported a greater incidence of infarction. 
ventricular arrhythmias, stroke, hemorrhage and death in 
patients who had successful recanalization than in patients 
whose grafts remained occluded. In some Casey. myocardial 
infarction is pain&i, sugcsting Illilt this mily bc m0rC CWlb 
man Ihan previously suspcctcd (SO). Tbc mechanism of some 
of these complications has not been de Iled, but they IlMy 
result from distal embolization of a partially Iysed lbrombus 
compromising the collateral blood supply. 
Finally, the long-term patency of these recanalized vein 
grafts is limited. In the ROBUST study (XT), 50% of grafts had 
reoccluded within h months despite therapy with aspirin and 
warfarin. 
Only a prospective, randomized trial can answer whether a 
prolonged urokinasc infusion in this setting improves angio- 
plasty outcome. However, in view of the reported complica- 
tions of this modality and the limited long-term patency rates, 
prolonged infusion should not presently be adopted as a 
routine method for rccanalizing chronic total occlusions. 
Acute vessel occlusion, the most common serious compli- 
cation of angioplasty, has been reported to occur in 2% to 11% 
of angioplasties (1,2,4,7). Thrombolysis as a rescue strategy for 
angioplasty complicated by acute vessel occlusion or thrombus 
formation h KWW bCC~ compared in clinical trials with oihCr 
I’C’SCUC Str~tcgies. SUCI? ;IS prolonged bijllO6,n infjations wit,11 
perfusion catbctcrs. Seven studies (7.37...!l.h7-70) enrolling 
I-i5 patWIts have examined the sole of IhY)rnhl9l,Si!, in rc- 
csaahkhing Qatellcy e9f an acutely c9ccluded vcsseli. Thrombol- 
ysi~ ws most often administrred in conjunction wirb or 
immediately after repeated balloon inflations and rarely as the 
sole therapy. Successful angioplasty was subsequently achieved 
in ‘50~6 of CZXS. Complications (myocardial infarction, emer- 
gcncv bypass surgery, deat 
r$Kree groups of investi 
occurred in 51% of cases, 
ors (37.71.72) administered intra- 
coronary urokinase for intracoronary thr:9mbus L9rmation dur- 
ing angioplasty before progression to complete occlusion. 
Illowcvcr. most of the tbrombi that were so trcnted cxbibitcd 
occlusive h&ilViOr and wcrc rncroaclIi?lg on the coronary 
lumCn bcforc urokinasc ;Idministlation. Such a strategy Was 
~lsSl9ciillcd with ;I SlKcCSSfUl angioplasty ~91~tc0mc in 30 (74% ) 
trl’ 01 (m6ic.m. \h,*rcYrs 2.4 (Z-i!‘; ) 01’ %t plkclP3 sustained 
serious ccamplicasions. 
iI SUCCChSfUl OUlCOmc Of thrOmh9lylic Ihcrilpy i~dmilliStcrCd 
for ilCUlC vcsssl occlusion 01’ intracoranary tlirombus form;!tion 
is less likely to bc achieved in the presence of concomitant 
intimal dissection (37,h7,72). This may b due to intraplaque 
hemorrhage promoted by tbrombolysis. owcvcr, it is often 
not possible to precisely dclinc lbc ctiolog,y. rhat is, ahrombus 
versus dissection. in many GISCS of threatened vessel occlusion 
during anpioplasty. 
Fiflidly. preliminary investigations (73-75) of prolonged 
intracoronary urokinase infusions in patients whose angioplas- 
tics are complicated by thrombus k9rmation have reported 
conflicting results on the benefits and Cl9mQ~iCiltil9llS Of this 
strategy. Additiclnal ev;lIuation of this thcrapcutic i\Itcrnittive is 
IlCCdCJ. 
Most research on the topic of thrombolysis and angioplasty 
for acute myocardial infarction has focused on defining the 
role of ungioplasly after successful thrombolytic therapy. Re- 
cently, several trials (X,77) have compared direct, primary 
angioplasty with thrombolytic therapy for the trcatmcnt of 
acute myocardial infarction and have demonstrated that an- 
gioplasty has a high success rilte and prevents recurrent 
ischcmia more effectively than thrombolytic tl 
cnt thrombolytic therapy could conceivably i 
come of angioplast acute myocardial infarction by reduc- 
ing clot burden. ever, palbologic CXa~llillilli~9llS haVc 
revtxhd intramural hemorh~gc: at the angioplasty dilation site 
in smw p;dC~~ts wit11 ;I myocardial infarction who rcccivcd 
antecedent thrombolysis (7X-W)). Occasionally. this hcmor- 
rhage has been associated with cncroachmcnt (91t the vcsscl 
lumen (78). 
Three studies (81-83) have addressed the qucslion of the 
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impact of i~9~~~~~~~~9~ ~~~~9~~~~91~~~~ lit9 angi~~~~s~ outcome 
and mortality in patients underg~~~?~ direct angiop~~sty for 
acute myoCardial infarction (Fig. 3). Only one of the three 
studies was a randamized, prospective cliniczf trial (81). In or16 
study, strcptokinase was used (131); in another, either strep 
tokinase or tissue-type plasminogen activator (t-PA) was ad- 
ministered (83); and in the third, details of thrombolysis were 
not specified (82). In the pooled analysis, neither the angio- 
plasty sutzzess rate (odds ratio 2.05,95% CT 0.83 to 5.07) nor 
the mortality rate (odds ratio 1.34, 95% CI 0.M to 2.73) was 
improved by antecedent thrombolysis. The analysis of angio- 
plasty success rates included 39‘7 patients with a 94.7% angio- 
plasty success rate in the control group. To detect a 50% or 
2S% improvement in angioplasty success rates, there would 
have to be Xl8 and 4,141 patients, respectively, in the analysis. 
Furthermore, several recent trials of primary angioplasty 
(without thrombolysis) for acute myacardial ~nf~rcti~R 
plasty success rates of ~.~~~~ (~~~~4,$5)” a 
Id be difficult to improve in any eirCumstance. 
efore, it is unlikely that thrombolytic therapy will be 
demonstrated to improve angioplasty outcome in this setting. 
In the mortality rate analysis, there were 659 patients with a 
6.4% death rate in the control group. To achieve an 80% 
chance of detecting a 50% reduction or a 25% reduction in 
mortality, there would need to be 706 and 3,279 patients, 
res~Ctively. The beta erron of the individual trials are sum- 
marized in Table 1. Thus, we conclude that antecedent throm- 
bolysis is not likely to improve angioplasty success rates in the 
setting of acute myocardial infarction, whereas insufficient data 
are ~~~~il~~lc to assess the impact on mortality rates. 
sis 
With the recognition of the role of activated platelets and 
platelet-derived growth factor in the pathogenesis of restenosis 
after angioplasty, there has been considerable interest in 
examining whether antithrombotic therapy can prevent resten- 
ra~hy. Alth~~u~~ there was no di~e~en~e in the 
rcstenusis, th:re WBS a tr~~ld for ~r~)ki~as treated patients lo 
have restenosis lesions of lesser severity. ecause the criteria 
for ~~orrni~~ follo~~~~ a~~~i~~grapbi~ e~~l~~t~~~ were not 
that incomplete ar :xaphic ‘t;lllow-up 
ant selection bias. Gishita et al. (89) 
retrospectively au~~~y2ed their results; in patients M~d~~goi~g 
primary a~gio~~as~ for acute myocardial infarction. 0f 70 
patients who bad angiogra~b~~ evidence of thrombrrs after 
essful angioplasty, 27 received iotr~~corona~ ~rokin~~se. 
l-month restenosis rate was 4% in the urokinase-treated 
in the patients not receiving urokinase (p < 
rishita et al. (89) to Conclude that thrombol- 
nosis. Because the study was retrospective, 
treatment assignment was not randomized, and angiographic 
follow-up was incomplete and was Mndertaken very early after 
angioplasty, this study cannot conclusively establish whether 
thrombolytic therapy reduces restenosis. 
The currently available data have not yet established a 
benefit of adjunctive thrombolysis in improving ang~o~~as~ 
success rates or decreasing angioplasty complication rates in 
routine, elective angioplasty or in acute myocardial nfarction. 
In unstable angina, the data suggest that antecedent thrombol- 
ysis may be detrimental. 
The outcome of prolonged administration f thrombolytics 
for chronic total occlusions may not be superior to conven- 
tional angioplasty, and this procedure has been associated with 
complications and limited long-term patency rates. Random- 
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